Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
Top Page
Rani Therapeutics Holdings
(NASDAQ:RANI)
32Underperform
Positive Factors
Financial Stability
Rani expects its cash runway to last into 3Q25 without additional funding, which suggests financial stability.
Market Opportunity
The obesity market opportunity is large (projected to eclipse $100B by 2030), so there is a sizeable opportunity for RT-114 as a more tolerable, orally administered Tx option with a biologic payload.
Strategic Development
The initiation of a Phase 1 trial for RT-114 in obesity, utilizing innovative RaniPill capsule technology, represents a significant development step.
Negative Factors
Partnership and Market Risks
Risks include, but are not limited to: negative Phase 2 data; negative clinical readouts with other candidates; failure to achieve approvals for key pipeline projects; possible partnership risk; slower-than-projected market uptake.
Regulatory and Clinical Risks
Risks include potential negative Phase 2 data and failure to achieve approvals for key pipeline projects.
Rani Therapeutics Holdings (RANI) vs. S&P 500 (SPY)
Market Cap
$61.57M
Dividend YieldN/A
Average Volume (3M)179.45K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue GrowthN/A
EPS Growth20.85%
CountryUS
Employees105
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.05
Shares Outstanding33,570,250
10 Day Avg. Volume164,979
30 Day Avg. Volume179,447
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.51
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside834.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Rani Therapeutics Holdings Business Overview & Revenue Model
Company DescriptionRani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
How the Company Makes MoneyRani Therapeutics Holdings generates revenue primarily through the development and commercialization of its RaniPill technology. The company earns money by partnering with pharmaceutical companies to develop oral versions of existing injectable biologics. These partnerships often involve research and development collaborations, licensing agreements, and milestone payments. Rani may also receive royalties from the sale of drugs developed using its technology. Additionally, the company may engage in direct sales of its RaniPill technology or related products once they receive regulatory approval and enter the market.
Rani Therapeutics Holdings Financial Statement Overview
Summary
Rani Therapeutics Holdings has shown no revenue generation, persistent net losses, and a heavily leveraged balance sheet. Despite some cost containment, the financial outlook remains weak with ongoing cash burn and limited equity.Income Statement
Rani Therapeutics Holdings has consistently reported zero revenue over the past three years, indicating a lack of sales activity or product commercialization. The company has also faced persistent net losses, which have slightly improved from $63.34 million in 2022 to $30.02 million in 2024. EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.15
Very Negative
Balance Sheet
The company's balance sheet shows a weak equity base with stockholders' equity consistently declining each year. The debt-to-equity ratio is high due to significant liabilities compared to equity, raising concerns over financial leverage. The equity ratio is low, indicating a heavy reliance on debt financing. These factors may pose financial risks if the company cannot achieve profitability or secure additional funding.30
Negative
Cash Flow
Rani Therapeutics Holdings has consistently experienced negative operating and free cash flows, indicating cash burn issues. Despite some reduction in free cash flow deficits, the company still struggles to generate positive cash flow from operations. The operating cash flow to net income ratio remains negative, highlighting challenges in converting sales into cash.20
Very Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.03M | 0.00 | 0.00 | 2.72M | 462.00K | Gross Profit |
| 1.03M | -822.00K | -1.31M | 2.72M | 462.00K | EBIT |
| -53.31M | -66.10M | -63.45M | -51.60M | -16.54M | EBITDA |
| -50.52M | -65.28M | -60.89M | -52.08M | -15.96M | Net Income Common Stockholders |
| -30.02M | -33.97M | -63.34M | -53.09M | -16.70M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 27.64M | 48.54M | 98.48M | 117.45M | 73.06M | Total Assets |
| 36.63M | 57.92M | 108.03M | 124.21M | 79.42M | Total Debt |
| 20.10M | 30.10M | 30.21M | 0.00 | 3.77M | Net Debt |
| 16.33M | 24.23M | 3.21M | -117.45M | -69.29M | Total Liabilities |
| 33.14M | 32.47M | 34.02M | 2.64M | 192.75M | Stockholders Equity |
| 1.99M | 12.87M | 36.85M | 47.41M | -113.34M |
| Cash Flow | Free Cash Flow | |||
| -35.76M | -52.47M | -48.13M | -32.75M | -16.16M | Operating Cash Flow |
| -35.50M | -51.24M | -46.52M | -32.24M | -14.96M | Investing Cash Flow |
| 19.81M | 29.86M | -72.44M | -506.00K | -1.20M | Financing Cash Flow |
| 13.59M | 233.00K | 29.00M | 77.15M | 72.68M |
Rani Therapeutics Holdings Technical Analysis
Negative
1.07
Price Trends
1.35
Negative
1.43
Negative
1.98
Negative
Market Momentum
-0.07
Negative
38.59
Neutral
38.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RANI, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.35, and below the 200-day MA of 1.98, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 38.59 is Neutral, neither overbought nor oversold. The STOCH value of 38.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RANI.
Rani Therapeutics Holdings Risk Analysis
Rani Therapeutics Holdings disclosed 102 risk factors in its most recent earnings report. Rani Therapeutics Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rani Therapeutics Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
43 Neutral | $91.37M | ― | -59.34% | ― | ― | 64.71% | |
42 Neutral | $71.35M | ― | -144.41% | ― | -72.22% | 51.40% | |
39 Underperform | $87.72M | ― | -65.08% | ― | -86.62% | ― | |
36 Underperform | $74.43M | ― | -55.14% | ― | -99.43% | -69.40% | |
34 Underperform | $82.79M | ― | -155.76% | ― | 25.77% | 32.56% | |
32 Underperform | $61.57M | ― | -404.07% | ― | ― | 20.85% |
* Healthcare Sector Average
Performance Comparison
RANI
Rani Therapeutics Holdings
1.07
-6.08
-85.03%
CRBP
Corbus Pharmaceuticals
7.52
-31.25
-80.60%
ADVM
Adverum Biotechnologies
3.33
-7.10
-68.07%
IGMS
IGM Biosciences
1.34
-8.73
-86.69%
ADAG
Adagene
1.58
-0.83
-34.44%
TCRX
TScan Therapeutics
1.55
-7.01
-81.89%
Rani Therapeutics Holdings Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: -15.08%|
Next Earnings Date:May 07, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.Q4-2024 Updates
Positive Updates
Advancements in RaniPill Technology
The RaniPill technology, designed for oral delivery of biologics, has shown success in preclinical and clinical trials, achieving high bioavailability for 19 molecules and completing three Phase 1 studies with no serious adverse events.
Progress in Obesity Treatment Pipeline
Rani made significant advancements in their obesity treatment pipeline, particularly with RT-114 and semaglutide programs, expecting the obesity market to reach $100 billion by 2030.
Successful Preclinical Data for RT-116
RT-116 demonstrated comparable pharmacokinetics and weight loss to subcutaneous administration with a relative bioavailability of 107% in preclinical studies.
RT-114 Preclinical Success
RT-114 showed higher Cmax and earlier Tmax than subcutaneous PG-102, with a relative bioavailability of 111% and equivalent weight loss in canine studies.
Strategic Partnership with ProGen
Rani entered a co-development agreement with ProGen for RT-114, combining ProGen's GLP-1/GLP-2 molecule with RaniPill technology.
Negative Updates
Decreased Financial Reserves
Cash, cash equivalents, and marketable securities decreased from $48.5 million in 2023 to $27.6 million in 2024, with funding expected to last into Q3 2025.
Impairment Loss
Rani recorded an impairment loss of $3.7 million related to certain manufacturing property and equipment.
Net Loss for 2024
The net loss for 2024 was $56.6 million, including an impairment loss of $3.7 million and stock-based compensation expense of $16 million.
Company Guidance
During Rani Therapeutics' fourth quarter and full year 2024 earnings call, guidance was provided on the company's strategic focus and financial outlook. The company emphasized advancements in its RaniPill platform, highlighting its application in obesity and immunology spaces. Rani plans to further develop its RT-114 and semaglutide programs, with RT-114 moving into clinical trials by mid-2025. Financially, Rani reported a net loss of $56.6 million for the full year, an improvement from $67.9 million in 2023, partly due to cost containment measures. The company ended the year with $27.6 million in cash and expects this to fund operations into the third quarter of 2025. Additionally, Rani is exploring partnership opportunities to leverage its platform technology across multiple indications.Rani Therapeutics Holdings Corporate Events
Executive/Board Changes
Rani Therapeutics Board Restructures After DeBuono’s Retirement
Neutral
Apr 30, 2025
On April 24, 2025, Laureen DeBuono retired from the Board of Directors of Rani Therapeutics Holdings, Inc., with her decision not stemming from any disagreements with the company. Her departure led to a reconstitution of the Board’s committees, with new chairs and members appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees.
Spark’s Take on RANI Stock
According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.
Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.
To see Spark’s full report on RANI stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.